A Phase 2 Study of BV-AVD in People With Newly Diagnosed Bulky Hodgkin Lymphoma

Full Title

BV-AVD in Patients with Newly-Diagnosed, Early Stage, Bulky Hodgkin Lymphoma using a PET-adapted and MTV-guided Approach

Purpose

BV-AVD is a combination of drugs used to treat advanced (stage 3 or 4) Hodgkin lymphoma. Researchers in this study want to see how well it works to treat early-stage bulky Hodgkin lymphoma. The people in this study have stage 1 or 2 bulky Hodgkin lymphoma that has not yet been treated.

BV stands for brentuximab vedotin. It targets cells that have the protein CD30, which plays a role in cancer growth. AVD includes the chemotherapy drugs doxorubicin, vinblastine, and dacarbazine. All of these medications are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have stage 1 or 2 bulky Hodgkin lymphoma that has not yet been treated.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Robert Stuver at 646-608-4308.